AzTrials
AzTrials

Intervertebral Disc Disorder CervicalNCT02967575

Triadyme-C, a Polycrystalline Diamond Compact Cervical Disc Replacement (cTDR)

An observational study of Intervertebral Disc Disorder Cervical, run by Dymicron at 4 sites in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This Post Market Clinical Follow-up (PMCF) is conducted to collect clinical and radiographic outcome information on patients suffering from intractable symptomatic cervical disc disease requiring 1- or 2-level reconstruction of the disc from C3-C7, after being treated with the Triadyme-C polycrystalline diamond… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Intervertebral Disc Disorder Cervical
What is being tested?
cTDR
Type of treatment
Medical device
How many people
100 participants
Where
4 sitesGermany
Study dates
Nov 2016to Oct 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Primary care clinic of selected spine centers

Who may be able to join

  • 1- or 2-level cTDR surgery between C3 and C7
  • Age ≥ 18 years
  • Skeletally mature patient
  • Patient suffers from intractable symptomatic cervical disc disease (SCDD) with neck or arm (radicular) pain and/or a functional/neurological deficit
  • At least one of the following conditions must be present and confirmed by radiographic (CT, MRI, x-ray, etc.) studies: herniated nucleus pulposus, spondylosis (indicated by the presence of osteophytes), or loss of disc height.
  • At least six weeks of non-operative treatment for SCDD has been tried and failed prior to implantation
  • Psychosocially, mentally, and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.
  • Patient signed Informed Consent

Who cannot join

  • Active systemic infection or infection localized to the site of implantation
  • Allergy or sensitivity to the implant materials
  • Osteoporosis, defined as a Dual-energy X-ray Absorptiometry (DXA) bone mineral density T-score equal to or less than -2.5
  • Marked cervical instability on radiographs (e.g., radiographic signs of subluxation greater than 3.5 mm or angulation of the disc space more than 11 degrees greater than adjacent segments)
  • Severe spondylosis characterized by bridging osteophytes or an absence of motion (less than 2 degrees)
  • Significant cervical anatomical deformity or compromised vertebral bodies at the index level (e.g. ankylosing spondylitis, rheumatoid arthritis, or compromise due to current or past trauma)
Show all 20Show fewer
  • Significant kyphotic deformity or significant reversal of lordosis
  • Previous cervical spinal surgery, other than discectomy at the levels to be operated on
  • Use of any spinal implant other than Triadyme-C
  • Adiposity, severe obesity (BMI > 40 kg/m2)
  • Patient who takes immunosuppressive or long-term steroid use
  • Fever
  • Systemic or metabolic illnesses (i.e. disease of bone-metabolism, insulin-dependent diabetes ...)
  • Patient who is suffering from rheumatoid or other inflammatory joint disease
  • Patient with any known active malignancy within the last 2 years
  • Any medical or surgical condition that could preclude the potential success of the implantation
  • Psychosocial issues; lack of co-operation by the patient, drug abuse or alcoholism
  • Unwillingness or inability of the patient to follow the instructions for postoperative treatment or with the follow-up evaluation schedule
  • Female patient who is pregnant or plans to become pregnant during the course of the study
  • Prisoner

Trial locations and contacts

4 sites in 1 country.

Germany4 sites
  • Charité Universitätsmedizin Berlin Klinik für Unfall- und Wiederherstellungschirurgie

    Berlin, 12203

  • STENUM Ortho GmbH

    Ganderkesee, Lower Saxony, 27777

  • Orth.med

    Kümmersbruck, Bavaria, 92245

  • Klinikum der Universität Rostock Abteilung für Neurochirurgie

    Rostock, Mecklenburg-Vorpommern, 18055

Other trials in Germany

About this study

Official title: Triadyme-C, a Polycrystalline Diamond Compact Cervical Disc Replacement (cTDR): Evaluation of Clinical and Radiographic Outcome

This Post Market Clinical Follow-up (PMCF) is conducted to collect clinical and radiographic outcome information on patients suffering from intractable symptomatic cervical disc disease requiring 1- or 2-level reconstruction of the disc from C3-C7, after being treated with the Triadyme-C polycrystalline diamond compact cervical disc replacement.

Read the detailed description

Approximately fifty percent of the population has evidence of degenerative changes in their cervical spine by the age of fifty. As part of the aging process, the intervertebral discs wear out. They lose their flexibility and elasticity and begin to collapse or even herniate. This process may result in a pathological condition called cervical Degenerative Disc Diseases (cDDD). cDDD can either be asymptomatic or symptomatic, showing different symptoms such as neck, shoulder, head, arm or leg pain, possibly associated with numbness, tingling or weakness in the upper extremity. In most cases symptomatic cDDD is initially treated conservatively with rest, immobilization, physical therapy, chiropractic manipulation and pain medication. For those cases not responding to conservative therapy, anterior cervical discectomy and fusion (ACDF) is a standard technique. The primary purpose of ACDF is to excise any disc material (discectomy), which compresses the spinal nerve or cord causing pain, sensory disturbance or weakness at the affected level, followed by interbody fusion of the adjacent vertebrae using grafts or intersomatic devices to compensate the instability and the loss of disc height resulting from discectomy. Despite the success of this common procedure, some disadvantages are to be mentioned including donor site morbidity when autografts are used, graft or device subsidence or pseudarthrosis of the segment to be fused. Besides this, physiological motion of successfully fused segments is no longer possible. This alters the loading and kinematics of adjacent spine segments which is believed by some authors to lead to adjacent segment overload as reported by several clinical and biomechanical studies. To address the disadvantages of ACDF, cervical total disc replacement (cTDR) has been developed in the 1990s, with the aim to carry the load and restore the normal disc height while preserving almost physiological segmental motion.

Today, several different cTRD designs are on the market, some of them with mid- to long-term results. A number of randomized controlled trials indicate clinical equivalence or even superiority of cTDR in some aspects compared to ACDF.

The Dymicron Triadyme-C cTDR is a two-piece articulating artificial disc prosthesis. Its patented tri-lobe articulation mechanism consists of three spherical lobes mating to three non-congruent, spherical pockets. The motion of these three lobes within their associated pockets emulates and controls natural motion of the cervical spine motion segment in all degrees of freedom.Triadyme-C is a self-centering device. This is achieved by the implant growing in height as it moves away from its center. The further away from center, the tighter the ligaments will be stretched. Each half of the Triadyme-C is a sintered monobloc, consisting of a polycrystalline diamond (PCD) bearing surface with a base of titanium-titanium carbide (Ti-TiC) composite. PCD is a sintered material composed of fused diamond crystals (typically more than 90%) and a small amount of catalyst sintering metal. The polycrystalline structure of diamond, together with the small amount of residual metal alloy, contributes significantly to the extraordinary toughness and abrasion-resistance of the material. PCD retains many of the phenomenal properties of natural diamond, including hardness, but in an isotropic form that is far more resistant to fracture.

This Post Market Clinical Follow-up (PMCF) is conducted to collect clinical and radiographic outcome information on patients suffering from intractable symptomatic cervical disc disease requiring 1- or 2-level reconstruction of the disc from C3-C7, after being treated with the Triadyme-C polycrystalline diamond compact cervical disc replacement.

Being tested
cTDR
Keywords
cervical total disc replacement (cTDR)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cTDRDevice

    Also called cervical Total Disc Replacement

    The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:

    • Implantation through a standard anterior cervical approach
    • Midline identification
    • Routine discectomy with endplate preparation and decompression
    • Implant sizing and trial implantation
    • Keel preparation
    • Implant preparation and loading of the appropriate Triadyme-C implant
    • Triadyme-C insertion, positioned as close to the midline as possible
Study groups in NCT02967575
Study groupRoleWhat they receive
1- or 2-level cTDRpatients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
Receives: Device: cTDR

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Neck Disability Index (NDI)

    Clinical outcome is measured by the Neck Disability Index (NDI) as published by Vernon et. al.. The primary endpoint of the study will be the mean total NDI at the 2 year postoperative assessment.

    Measured: 2 years postoperative

Secondary outcomes (6)
  1. Visual Analogue Scale (VAS) on neck pain

    The Visual Analogue Scale (VAS) represents the subject's intensity of neck pain during the last week measured on a line of 10 cm length, stretching from 'no pain (0 cm) to 'pain as bad as it could be' (10 cm).

    Measured: 2 years postoperative

  2. Visual Analogue Scale (VAS) on arm pain

    The VAS represents the subject's intensity of pain experienced in the pain-dominant arm during the last week measured on a line of 10 cm length, stretching from 'no pain (0 cm) to 'pain as bad as it could be' (10 cm).

    Measured: 2 years postoperative

  3. Rate of device failure

    Failure rate is based on the number of subjects whose radiographs, MRIs and/or CTs showed one or more device failures during the 2 year follow-up period after implantation divided by the total number of patients with 2 year radiographs or earlier failures.

    Measured: 2 years postoperative

  4. Rate of subsequent surgical interventions

    The following subsequent surgical intervention rates at index level are secondary study endpoints

    • removal
    • revision
    • reoperation
    • supplemental fixation

    Each subsequent surgical intervention rate is based on the number of subjects who showed one or more surgical interventions at index level per category during the 2 year follow-up period after implantation divided by the total number of patients with 2 year results or earlier subsequent surgical interventions.

    Measured: 2 years postoperative

  5. Range of motion at index level

    Range of motion (ROM) at index level means the degree of flexion/extension motion in the replaced segment. It is measured along the endplates according to the technique of Cobb in degrees in the sagittal plane on active lateral flexion and extension radiographs. ROM is defined as the difference of endplate alignment (Cobb angle) in maximum active flexion and maximum active extension per follow-up examination.

    Measured: 2 years postoperative

  6. Rate of subsequent surgical interventions at symptomatic adjacent levels

    The rate of subsequent surgical interventions at symptomatic adjacent levels is based on the number of subjects who underwent subsequent surgery to treat progressive adjacent segment disease during the 2 year follow-up period after implantation divided by the total number of patients with 2 year results or earlier adjacent subsequent surgical interventions.

    Measured: 2 years postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2016 (estimated)
  2. Study startNov 2016
  3. Primary completionMay 2020 (estimated)
  4. Study completionOct 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02967575
Sponsor's protocol ID
CIP 16/01
Status last verified
Nov 2018
First submitted
15 Nov 2016
Last updated
29 Nov 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Intervertebral Disc Disorder Cervical, run by Dymicron at 4 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Neck Disability Index (NDI) (time frame: 2 years postoperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in